Several other equities analysts have also recently commented on ZTS. Zacks Investment Research cut shares of Zoetis from a buy rating to a hold rating and set a $242.00 target price for the company. in a research report on Saturday, January 8th. Citigroup decreased their price target on shares of Zoetis from $232.00 to $208.00 and set a neutral rating on the stock in a report on Wednesday, March 9th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis has an average rating of Buy and a consensus target price of $224.78.
Shares of ZTS opened at $187.30 on Friday. The firm has a 50-day moving average of $192.30 and a 200-day moving average of $207.11. Zoetis has a one year low of $163.93 and a one year high of $249.27. The company has a market cap of $88.37 billion, a PE ratio of 43.86, a price-to-earnings-growth ratio of 3.21 and a beta of 0.77. The company has a debt-to-equity ratio of 1.45, a current ratio of 3.86 and a quick ratio of 2.79.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 1st. Investors of record on Thursday, April 21st will be issued a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, April 20th. This represents a $1.30 dividend on an annualized basis and a yield of 0.69%. Zoetis’s dividend payout ratio (DPR) is presently 30.45%.
In other news, EVP Roman Trawicki sold 6,000 shares of Zoetis stock in a transaction dated Wednesday, March 16th. The shares were sold at an average price of $188.15, for a total value of $1,128,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Glenn David sold 32,390 shares of Zoetis stock in a transaction dated Wednesday, February 23rd. The stock was sold at an average price of $189.87, for a total transaction of $6,149,889.30. The disclosure for this sale can be found here. Insiders have sold 50,455 shares of company stock valued at $9,607,544 in the last 90 days. 0.17% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. IFM Investors Pty Ltd lifted its holdings in shares of Zoetis by 16.4% in the 1st quarter. IFM Investors Pty Ltd now owns 73,646 shares of the company’s stock worth $13,889,000 after acquiring an additional 10,364 shares during the last quarter. Atticus Wealth Management LLC lifted its holdings in shares of Zoetis by 22.0% in the 1st quarter. Atticus Wealth Management LLC now owns 677 shares of the company’s stock worth $128,000 after acquiring an additional 122 shares during the last quarter. Peoples Financial Services CORP. bought a new stake in shares of Zoetis in the 1st quarter worth approximately $132,000. Ritholtz Wealth Management increased its stake in shares of Zoetis by 40.0% in the first quarter. Ritholtz Wealth Management now owns 5,207 shares of the company’s stock worth $982,000 after buying an additional 1,487 shares during the period. Finally, Stony Point Wealth Management Inc. increased its stake in shares of Zoetis by 40.6% in the first quarter. Stony Point Wealth Management Inc. now owns 11,182 shares of the company’s stock worth $2,109,000 after buying an additional 3,230 shares during the period. 90.36% of the stock is owned by institutional investors.
Zoetis Company Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.